




Patient no.	Age (y.)	Sex (F/M)	Histology at first diagnosis	Treatment arm	Axitinib at 6 wks (mg)	Evolution of corticosteroid treatment	Best Overall Response	
							6 wks	12 wks
1	48	F	de novo GBM	Axitinib+CCNU	7	decrease	uPR	PR
2	63	M	de novo GBM	Axitinib+CCNU	2	decrease	uPR	PR
3	24	M	grade 2 astrocytoma	Axitinib	5	increase	uPR	PD
5	57	F	grade 2 astrocytoma	Axitinib+CCNU	7	stable	uPR	PD
6	39	F	de novo GBM	Axitinib+CCNU	5	decrease	uPR	PD
7	64	M	de novo GBM	Axitinib	5	decrease	uPR	PD
8	51	F	de novo GBM	Axitinib	5	decrease	uPR	PD
9	59	F	de novo GBM	Axitinib	5	decrease	uSD	SD
10	53	M	de novo GBM	Axitinib+CCNU	5	stable	uSD	SD
11	44	M	grade 2 astrocytoma	Axitinib+CCNU	3	increase	PD	
12	48	M	de novo GBM	Axitinib+CCNU	5	stable	uSD	SD
14	69	F	de novo GBM	Axitinib	5	decrease	uPR	PR
15	35	M	de novo GBM	Axitinib	5	stable	uPR	PD
16	64	M	grade 3 oligodendroglioma	Axitinib	5	stable	uPR	PR
17	52	M	grade 3 oligodendroglioma	Axitinib	7	stable	uPR	PR
18	57	F	de novo GBM	Axitinib	5	stable	uPR	PD
19	48	M	anaplastic astrocytoma	Axitinib	7	decrease	PD	
20	28	M	de novo GBM	Axitinib+CCNU	5	stable	SD	SD

Supplementary table 1: patient characteristics and tumor response



Supplementary Figure 1: Axitinib or axitinib plus lomustine does not influence the number of TEM CD4⁺ and CD8⁺ T cells. The percentages of T-cell subsets within CD4⁺ and CD8⁺ T cells were determined with flow cytometry after treatment with axitinib or axitinib plus lomustine. Gating strategy for the determination of the different T cells subsets (a). Percentages of T_{CM} CD4⁺ T cells (b) and T_{CM} CD8⁺ T cells (c) as determined in absence or presence of anti-CD3/CD28 beads at baseline and at 6 weeks after axitinib (n=9) (upper panel) or axitinib plus lomustine treatment (n=6) (lower panel). Percentages of T_{EM} CD4⁺ T cells (CD45RO⁺ CD62L⁻ CD4⁺ T cells)(d) and T_{EM} CD8⁺ T cells (CD45RO⁺ CD62L⁻ CD8⁺ T cells)(e) as determined in absence or presence of anti-CD3/CD28 beads at baseline and at 6 weeks after axitinib (n=9) (upper panel) or axitinib plus lomustine treatment (n=6) (lower panel). Data are represented as median with interquartile range.

a.**b.**

Supplementary Figure 2: Axitinib or axitinib plus lomustine does not affect the co-expression of LAG3, TIM3 and PD-1 on CD4+ and CD8+ T cells

The percentages of LAG3, TIM3 and PD-1 were determined on CD4⁺ and CD8⁺ T cells at baseline and at 6 weeks after treatment. Percentages of LAG3⁺TIM3⁺CD4⁺ T cells (left panel), PD-1⁺LAG3⁺CD4⁺ T cells (middle part) and PD-1⁺TIM3⁺CD4⁺ T cells (right part)(a) and LAG3⁺TIM3⁺CD8⁺ T cells (left panel), PD-1⁺LAG3⁺CD8⁺ T cells (middle panel) and PD-1⁺TIM3⁺CD8⁺ T cells (right panel) (b) as determined after polyclonal stimulation at baseline and at 6 weeks after axitinib (n=9) (upper panel) or axitinib plus lomustine treatment (n=6) (lower panel). Data are represented as median with interquartile range.